Skip to content
type1.science

CamAPS FX

CamDiab (Cambridge, UK) / distributed by Ypsomed as mylife CamAPS FX

A phone-based hybrid closed-loop app running the adaptive Cambridge model-predictive-control algorithm. Uniquely licensed from age 1 and through pregnancy, it pairs with Dexcom and FreeStyle Libre 3 sensors driving the YpsoPump (and DANA pumps) — the broadest eligibility of any commercial system, backed by two NEJM randomized trials. UK/EU; not FDA-cleared.

Available nowStrong evidencehybrid-closed-loopphone-controltubedOfficial site ↗

The scorecard

Time in range74

Achieved real-world TIR of 69.6% (median, IQR 61.3-77.2) across 35,714 T1D users in 19 countries (Boughton et al., Metabologia 2026) is the most representative figure; a smaller 1,805-user real-world analysis reported a higher 72.6% ± 11.5%. By age, real-world TIR spans ~62.5% (young adults 18-22y) to ~76.1% (≥65y). Weighting toward the large, broad, multi-age cohort at ~70% places CamAPS FX at 74 on the achieved-TIR scale calibrated to the MiniMed 780G anchor (~76% = 80) — genuinely below the 780G anchor, kept conservative because the dominant dataset sits at ~70% rather than the smaller cohort's ~73%.[1]

Hypo protection76

Achieved real-world time-below-70 mg/dL (<3.9 mmol/L) was 2.5% (median, IQR 1.4-3.9) in the 35,714-user cohort and 2.3% (IQR 1.3-3.6) in the 1,805-user cohort, staying <4% across every age group. A TBR of ~2.3-2.5% maps to the 76-78 band (the calibration places ~2-2.5% at 76-78, ~3% at 72-74); CamAPS FX's well-controlled hypoglycemia at scale supports 76.[1]

Automation level70

Adaptive algorithm auto-titrates basal every 8-12 min and self-learns daily/meal patterns, but it remains hybrid: meals are announced. SMASH RCT showed simplified meal announcement is non-inferior to full carb counting.

Average glucose74

Achieved GMI was 7.1% ± 0.5% (mean glucose 8.7 mmol/L) in the 35,714-user real-world cohort and 6.9% (mean glucose 8.4 mmol/L) in the 1,805-user cohort. A GMI near 7.1% reflects solid but not class-leading average-glucose control, consistent with the ~70% achieved TIR; scored 74 to align with the time-in-range anchor.[1]

Low variability73

Glycemic variability is not reported as a coefficient of variation in the primary real-world dataset, but the consistent TBR (~2.5%) alongside a ~70% TIR and GMI 7.1% across a 35,714-user, all-ages cohort indicates good day-to-day stability without exceptional tightening. Scored 73, slightly below the TIR anchor to reflect the absence of a directly reported low-CV figure and the conservative read of the larger cohort.[1]

Exercise handling74

Dedicated Ease-off (raises target, cuts insulin for activity) and Boost (raises insulin) modes; real-world analysis of 7,464 users found Ease-off lowered time above range with no safety signal.

Customizability84

Fully adjustable personal glucose target 4.4-11.0 mmol/L (default 5.8) by time of day, plus Boost/Ease-off and slowly-absorbed-meal options — among the most tunable commercial systems.

Access & cost55

Available across UK/EU (and Australia/others) on Android and, since 2025, iOS; reimbursed in several systems. Not FDA-cleared, so unavailable in the US.

Freedom (form factor)55

Runs on small tubed pumps (YpsoPump, Dana) — compact and discreet for a tubed system, but not a tubeless patch.

Glycemic criteria are scored on the levels actually achieved in large real-world Type 1 diabetes cohorts — not the headline improvement over a trial's baseline (an improvement that looks bigger when the starting population was doing poorly). Type 2 diabetes trial data is never used to score a Type 1 system; where only improvement data exists, it informs the rationale, not the score. Freedom captures form factor and wearability, so a tubeless system is rewarded for the mobility a tubed one can't match.

The full picture

CamAPS FX is a hybrid closed-loop app for type 1 diabetes that runs the adaptive "Cambridge" model-predictive-control algorithm on a smartphone, where it links a continuous glucose monitor (CGM) to an insulin pump.1 Rather than being a single sealed device, it is the algorithm and app from CamDiab that drives compatible hardware: the mylife YpsoPump (a small tubed patch-style pump) and DANA Diabecare RS / DANA-i pumps, paired with Dexcom G6/G7 or Abbott FreeStyle Libre 3 / Libre 3 Plus sensors.12 The algorithm recalculates and adjusts insulin every 8-12 minutes from CGM readings, and continuously "learns" the user's daily, day-to-day and around-meal insulin needs.3

What the trials show. Its evidence base is unusually strong — two New England Journal of Medicine randomized trials. In very young children aged 1-7 years (KidsAP02, NCT03784027), CamAPS FX raised time-in-range (70-180 mg/dL) by 8.7 percentage points versus a sensor-augmented pump, cut mean glucose by 12.3 mg/dL and HbA1c by 0.4 points, with no increase in hypoglycemia.4 In pregnancy (AiDAPT), it lifted time in the tight pregnancy target (63-140 mg/dL) to 68.2% versus 55.6% on standard care — a 10.5-point gain — and reduced hyperglycemia.5 Benefits persisted through the first 6 months postpartum (72% vs 54% time-in-range).6 Real-world data from 1,805 users mirror the trials: average time-in-range 72.6% (rising to ~82% in users over 65) and a glucose management indicator (GMI, an estimated HbA1c) of 6.9%.7

How automated is it? It is a hybrid loop: it automates background (basal) insulin and adds automatic correction doses, but you still announce meals and enter carbohydrates so it can deliver a mealtime bolus.3 Encouragingly, a randomized trial (SMASH) found that simplified meal announcement — picking a meal "size" instead of counting carbs precisely — gave non-inferior time-in-range (69.9% vs 70.7%), easing one of the most tedious daily tasks.8

Exercise and customization. Two manual modes handle changing needs: Ease-off raises the glucose target and trims insulin ahead of exercise or other low-risk periods, and Boost increases insulin for illness or stubborn highs. A real-world analysis of 7,464 users found Ease-off reduced time above range and Boost was used safely, with no severe hypoglycemia or DKA attributed to either feature.9 Users can set a personal glucose target anywhere from 4.4 to 11.0 mmol/L (default 5.8 mmol/L), adjustable by time of day — among the most tunable commercial systems.10

Ages, indications and access. CamAPS FX is licensed for people with type 1 diabetes aged 1 year and older and is the only system specifically indicated for use in pregnancy, with a wide approved range of 5-350 units/day total daily insulin.12 (Minimum approved age varies slightly by sensor.) It carries a CE mark and is available across the UK, EU, Australia and some other markets — historically Android-only, with an iOS/iPhone version launched in 2025.211 It is not FDA-cleared, so it is not available in the US.

What's coming. The 2025 iOS launch (rolling out country by country) and a new mylife Cloud data-sharing function are expanding reach and remote monitoring.11 Broader sensor support (Libre 3 Plus, Dexcom G7) and additional pump partners continue to widen the choice of hardware,1 and the same Cambridge algorithm is being studied in fully closed-loop, no-meal-announcement configurations and in type 2 diabetes — the likely next frontiers for the platform.45

References

  1. CamDiab. CamAPS FX — closed-loop insulin delivery system for type 1 diabetes (compatible pumps, sensors, ages, pregnancy). https://camdiab.com/ ↩ ↩2 ↩3 ↩4

  2. Ypsomed. Ypsomed and CamDiab expand availability of mylife CamAPS FX on iOS (compatible YpsoPump + Dexcom G6 and FreeStyle Libre 3/3 Plus; ages; pregnancy), 10 June 2025. https://www.ypsomed.com/en/news-insights/news/press-releases/news-reader-detail-page/ypsomed-and-camdiab-expand-availability-of-mylife-camaps-fx-on-ios ↩ ↩2 ↩3

  3. CamDiab / Health Innovation Network. CamAPS FX closed-loop system specifications (adaptive model predictive control; adjusts every 8-12 min; default target 5.8 mmol/L). https://healthinnovationnetwork.com/wp-content/uploads/2021/11/CamAPS_FX_-Specifications.pdf ↩ ↩2

  4. Ware J, Allen JM, Boughton CK, et al. Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. N Engl J Med 2022;386:209-219. doi:10.1056/NEJMoa2111673. https://pubmed.ncbi.nlm.nih.gov/35045227/ ↩ ↩2

  5. Lee TTM, Collett C, Bergford S, et al. Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes (AiDAPT). N Engl J Med 2023;389:1566-1578. doi:10.1056/NEJMoa2303911. https://pubmed.ncbi.nlm.nih.gov/37796241/ ↩ ↩2

  6. Lee TTM, Collett C, Bergford S, et al. Automated insulin delivery during the first 6 months postpartum (AiDAPT extension). Lancet Diabetes Endocrinol 2025;13:210-220. doi:10.1016/S2213-8587(24)00340-1. https://pubmed.ncbi.nlm.nih.gov/39884300/ ↩

  7. Alwan H, Wilinska ME, Ruan Y, Da Silva J, Hovorka R. Real-World Evidence Analysis of a Hybrid Closed-Loop System (mylife CamAPS FX). J Diabetes Sci Technol 2025;19:385-389. doi:10.1177/19322968231185348. https://pmc.ncbi.nlm.nih.gov/articles/PMC11873883/ ↩

  8. SMASH investigators. Simplified meal announcement study (SMASH) using hybrid closed-loop insulin delivery in youth and young adults with type 1 diabetes. Diabetologia 2024. doi:10.1007/s00125-024-06319-w. https://pubmed.ncbi.nlm.nih.gov/39560745/ ↩

  9. Royston C, Bergford S, Calhoun P, et al. Safety of Options to "Boost" and "Ease-Off" in the CamAPS FX Hybrid Closed-Loop System: A Real-World Analysis. Diabetes Technol Ther 2025;27:60-65. doi:10.1089/dia.2024.0298. https://pmc.ncbi.nlm.nih.gov/articles/PMC7617696/ ↩

  10. Evaluating the Impact of Applying Personal Glucose Targets in a Closed-Loop System (CamAPS FX; default 5.8 mmol/L, adjustable 4.4-11.0 mmol/L). J Diabetes Sci Technol 2022. doi:10.1177/19322968221145184. https://pubmed.ncbi.nlm.nih.gov/36540007/ ↩

  11. Ypsomed. mylife CamAPS FX on iOS — 2025 expansion and mylife Cloud data sharing. https://www.ypsomed.com/en/news-insights/news/press-releases/news-reader-detail-page/ypsomed-and-camdiab-expand-availability-of-mylife-camaps-fx-on-ios ↩ ↩2

What's next for this

  • →iOS/iPhone version rolling out country by country · 2025
  • →New mylife Cloud data-sharing function for remote monitoring
  • →Broader sensor support (FreeStyle Libre 3 Plus, Dexcom G7) and additional pump partners
  • →Cambridge algorithm being studied in fully closed-loop (no meal announcement) and type 2 diabetes configurations

Sources

  1. [1]Real-world evidence on the CamAPS FX hybrid closed-loop system in people living with type 1 diabetes · peer-reviewed · 2026-01-01
  2. [2]Real-World Evidence Analysis of a Hybrid Closed-Loop System (CamAPS FX, 1,805 users / 15 countries) · peer-reviewed · 2023-01-01
  3. [3]AiDAPT: Closed-Loop Insulin Delivery in Pregnant Women with Type 1 Diabetes (NEJM) · peer-reviewed · 2023-01-01
  4. [4]Long-term assessment of the NHS hybrid closed-loop real-world study in children and young people with type 1 diabetes (incl. CamAPS FX) · peer-reviewed · 2024-01-01